Perspective Therapeutics CATX
NYSE CATX
$2.67 +0.06 (+2.10%)
As of: Sep 30, 2026 · 2:15 PM EDT

Perspective Therapeutics (CATX) Construction in Progress (2011)

Updated

Perspective Therapeutics (CATX) reported Construction in Progress of $123,613 for Q4 2011.

Analysis

Perspective Therapeutics (CATX) Construction in Progress (2011) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn -
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn -
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn -
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Perspective Therapeutics 298.91 Mn 298.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2011 123,613.00
API Access

Perspective Therapeutics Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=CATX&period=max&api_key=YOUR_API_KEY